Industry & Policy

OpenAI acquires Orchestra Bio to strengthen biotech AI capabilities

Original titleOpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Outlet: TechCrunch
Published: Oct 21, 2026
Importance: 5/5

Summary

OpenAI acquired startup Orchestra Bio to strengthen its Rosalind, an AI model for life sciences research, and its Rosalind Workbench tool that helps researchers plan experiments and analyze results.

Also reported by 1 outlet

OpenAI NewsOpenAI acquires Orchestra Bio

Original excerpt

OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.

#openai#biotech#rosalind

Read the original

See all →

Jun 9

OpenAI files confidentially for IPO, following Anthropic

OpenAI submitted a confidential Form S-1 filing with the SEC, following Anthropic's IPO filing from the previous week. The confidential filing means certain details such as executive compensation and business risks remain nonpublic.

TechCrunch

Jul 7

Samsung Electronics reports Q2 operating profit of KRW 89.4 trillion, up 1810% year-over-year

Samsung Electronics recorded a second-quarter operating profit of KRW 89.4 trillion, marking its third consecutive record quarter. The result represents a 1,810% increase from the same period last year, with revenue reaching KRW 171 trillion, up 129.3% annually. AI semiconductor demand drove the exceptional growth.

AI Times

Oct 6

Google limits free Gemini access starting October 9th

Starting October 9th, free Google Gemini users will be limited to the Flash Lite model. Access to the standard Flash model requires a $4.99 monthly Google AI Plus subscription, which will also stop including Gemini Pro. Top-tier Gemini Pro and Deep Think reasoning will be restricted to Google AI Pro or Ultra subscribers.

The Verge AI +1 more

Oct 7

DeepSeek nearly doubles pre-IPO funding to up to $15 billion

DeepSeek raised its pre-IPO funding target from $7.4 billion to between $12 billion and $15 billion as investor interest surged. CATL and Tencent Holdings are the lead investors.